ANI Pharmaceuticals (NASDAQ:ANIP) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report published on Tuesday morning, Benzinga reports. They currently have a $94.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q3 2024 earnings at $0.75 EPS.

ANIP has been the subject of a number of other research reports. Truist Financial reissued a hold rating and issued a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. StockNews.com downgraded ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $78.80.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $60.38 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The business has a 50-day moving average of $61.14 and a 200-day moving average of $63.76. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of 37.74 and a beta of 0.71. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same quarter in the previous year, the firm earned $1.06 EPS. The business’s quarterly revenue was up 18.5% on a year-over-year basis. As a group, sell-side analysts predict that ANI Pharmaceuticals will post 3.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the transaction, the senior vice president now owns 193,226 shares in the company, valued at approximately $12,258,257.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the transaction, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Muthusamy Shanmugam sold 11,000 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $63.38, for a total value of $697,180.00. Following the transaction, the chief operating officer now owns 671,620 shares in the company, valued at approximately $42,567,275.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,007 shares of company stock valued at $2,911,790. Company insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Texas Permanent School Fund Corp raised its stake in ANI Pharmaceuticals by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after purchasing an additional 172 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in ANI Pharmaceuticals by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after purchasing an additional 200 shares during the period. Arizona State Retirement System raised its position in shares of ANI Pharmaceuticals by 4.7% during the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after acquiring an additional 211 shares during the last quarter. Simplicity Wealth LLC raised its holdings in ANI Pharmaceuticals by 3.5% during the 2nd quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 227 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in ANI Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after buying an additional 233 shares during the period. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.